Bionano announces publication reporting first use of ogm to detect chromoanagenesis, a key marker of poor prognosis in aml

In-motion webinar: bionano will host a webinar featuring the study's lead author, dr. guilin tang, who will discuss the study and its findings in detail, including a summary of the potential implications for wide-spread adoption of optical genome mapping time and date: april 15, 2025 at 9:30 am central time, usa registration details to be made available at bionano.com san diego, march 13, 2025 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced a study published in the american journal of hematology demonstrating the potential utility of optical genome mapping (ogm) for detecting structural variants associated with chromoanagenesis (cag) in acute myeloid leukemia (aml). cag is a catastrophic genomic event that is frequently associated with highly complex karyotypes, extensive clonal heterogeneity, treatment resistance, and poor prognosis compared to subjects with no detectable cag.
BNGO Ratings Summary
BNGO Quant Ranking